ADX-097

Phase 2

Akebia Therapeutics, Inc. (AKBA)

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

5 competitors in IgA Nephropathy

VERAatacicept-vymj

KDNYAtrasentan

Phase 3

NVSBION-1301 Single Dose

Drug Information

Target Indication

IgA Nephropathy

Clinical Trial

NCT06419205

Last updated: 10/17/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

AKBA

Akebia Therapeutics, Inc.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

Mircera®Phase 3

Anemia Associated With Chronic Kidney Disease (CKD)

Darbepoetin alfaPhase 3

Anemia

Ferric Citrate 1 GM Oral TabletPhase 3

Anemia, Iron Deficiency

Erythropoiesis Stimulating AgentPhase 3

Anemia of Chronic Kidney Disease

Erythropoiesis-Stimulating Agent (ESA)Phase 3

Anemia of Chronic Kidney Disease

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts